Tumor hypoxia induces the upregulation of hypoxiainducible factor 1a (Hif-1a), which in turn induces the expression of genes including VEGF to recruit new blood vessel outgrowth, enabling tumor growth and metastasis. Interference with the Hif-1 pathway and neoangiogenesis is an attractive antitumor target. The hydroxylation of Hif-1a by prolyl-hydroxylase (PHD) proteins during normoxia serves as a recognition motif for its proteasomal degradation. However, under hypoxic conditions, hydroxylation is inhibited and furthermore, PHD proteins are themselves polyubiquitylated and degraded by Siah ubiquitin ligases. Our data demonstrate for the first time that inhibition of the interaction between Siah and PHD proteins using a fragment derived from a Drosophila protein (phyllopod) interferes with the PHD degradation. Furthermore, cells stably expressing the phyllopod fragment display reduced upregulation of Hif-1a protein levels and Hif-1-mediated gene expression under hypoxia. In a syngeneic mouse model of breast cancer, the phyllopod fragment reduced tumor growth and neoangiogenesis and prolonged survival of the mice. In addition, levels of Hif1a and its target Glut-1 are reduced in tumors expressing the phyllopod fragment. These data show, in a proof-ofprinciple study, that Siah protein, the most upstream component of the hypoxia pathway yet identified, is a viable drug target for antitumor therapies.
Introduction
Solid tumor growth is associated with areas of poor oxygen supply within the tumor mass. The main cellular response to hypoxic stress is the upregulation of hypoxia-responsive genes, including VEGF, Glut-1, and CA9 (Semenza, 1999) . The key transcription factor for the hypoxic response pathways is hypoxia-inducible factor 1 (Hif-1) (Iyer et al., 1998; Semenza, 2000; Schofield and Ratcliffe, 2004) . Hif-1 consists of two subunits, Hif-1a and Hif-1b. In the Hif-1 complex, the Hif-1a subunit is constitutively present within the cell, whereas Hif-1b is stabilized under hypoxic conditions (Semenza, 1999) . Under normoxia, Hif-1a is hydroxylated at two conserved proline residues (Pro402 and Pro564) by prolyl-hydroxylases (PHDs) (Epstein et al., 2001; Jaakkola et al., 2001) . The Pro402/Pro564 hydroxylated Hif-1a protein has increased affinity for the E3 ubiquitin-protein ligase complex composed of the von Hippel-Lindau tumor suppressor protein VHL, elongin B and C and cullin 2. After being polyubiquitylated, Hif-1a is degraded by the 26S proteasome (Salceda and Caro, 1997; Huang et al., 1998; Maxwell et al., 1999) . Furthermore, Hif-1a is hydroxylated at Asn803 by the asparaginyl hydroxylase factor-inhibiting Hif-1 (FIH) (Lando et al., 2002) . This hydroxylation prevents the interaction between Hif-1a and transcriptional co-activators CBP/p300 (Lando et al., 2002) . Recently, we and others have shown that, under hypoxic conditions, members of the Siah ubiquitin ligase family can polyubiquitylate and target PHD and FIH for proteasomal degradation (Nakayama et al., 2004 (Nakayama et al., , 2007 Khurana et al., 2006; Fukuba et al., 2007) , thus stabilizing Hif-1a.
Protein ubiquitylation is a three-step, enzymatic process (Hochstrasser, 2000) . The specificity of the process is defined by the final step in which a ubiquitin ligase, either alone or as part of a complex, transfers ubiquitin to the substrate protein (Glickman and Ciechanover, 2002) . Specificity is achieved by ubiquitin ligases recognizing specific degradation signals or 'degrons' (Laney and Hochstrasser, 1999) . Drosophila Seven in Absentia (SINA) and mammalian Seven in Absentia Homolog (Siah) are RING-containing proteins that function in protein degradation as ubiquitin ligases. In Drosophila, SINA has been shown to cooperate with Phyllopod (PHYL), Ebi and UBCD1 to facilitate the ubiquitylation and degradation of the transcriptional corepressor tramtrack 88 (TTK88) (Li et al., 1997; Tang et al., 1997; Boulton et al., 2000) .
In mammalian cells, Siah proteins can polyubiquitylate several seemingly unrelated proteins, with Siah1 and Siah2 having overlapping functions. Among the substrates are PHD1 and PHD3 (Nakayama et al., 2004) , corepressors such as nuclear corepressor (Zhang et al., 1998) and CTBP-interacting protein (Germani et al., 2003) , as well as the transforming growth factor-binduced early gene-1 (TIEG-1) (Johnsen et al., 2002) .
The human Siah1 and murine Siah1A and Siah1B differ to human and murine Siah2 only in their amino terminus (Della et al., 1993; Hu et al., 1997) . Siah is a dimeric protein consisting of an N-terminal RING domain followed by two novel zinc-finger motifs and a highly conserved C-terminal substrate-binding domain (Polekhina et al., 2002; House et al., 2006) . We have reported previously that many Siah-binding proteins contain a common binding motif that may act as a 'degron' or degradation signal centered around a VxP motif (House et al., 2003) . More recently, using the crystal structure, we have identified critical amino acids in the Siah1A protein, including the conserved Met180 and Lys158, that permit binding to interacting proteins (House et al., 2006) .
Here, we show the development of a small protein inhibitor of Siah function derived from the Drosophila PHYL sequence. Interference with the Siah substratebinding site inhibits Siah function due to reduced Siah/ substrate interaction. In cell-based assays, PHYL reduces Siah-mediated proteasomal degradation of PHD proteins. Cell lines with stable PHYL expression showed both reduced Hif-1a stabilization and Hif-1-mediated gene expression under hypoxic conditions. Tumors expressing PHYL grew more slowly compared to control tumors, had apparently reduced neo-angiogenesis and were associated with prolonged survival in a syngeneic mouse model of breast cancer. These data suggest that inhibitors acting at the Siah/substratebinding site may function as therapeutic agents.
Results
Regulation of PHD protein abundance by Siah is influenced by PHYL fragment A previous study had demonstrated that the PHD1 and PHD3 are important Siah2 substrates (Nakayama et al., 2004) . In U2OS, as well as HEK293 cells, (Figure 1a and data not shown) expression of Siah2 could mediate the reduction of PHD1 proteins levels. We sought to investigate the potential for overexpressed PHYL protein to act as an inhibitor of mammalian Siah. We expressed a stable fragment of PHYL (1-130) containing the previously reported binding motif (House et al., 2003) , the core residues of which are VxP (amino-acid residues 120-122). Mutation of this motif to NxN was previously shown to ablate Siah binding (House et al., 2003) . Wild-type PHYL fragment, but not PHYL NxN (VxP mutated to NxN) was able to recover the PHD1 protein levels to that of PHD1 expression without Siah2 (Figure 1a ). Consistent with previous reports (Nakayama et al., 2004) , Siah2 expression did not influence PHD2 protein levels, which were also unaffected by PHYL or PHYL NxN expression ( Figure 1b) . Expression of Siah2 together with PHD3, however, led to a very strong reduction of PHD3 levels (Figure 1c ), similar to those observed for PHD1. PHYL was again able to interfere with the reduction of PHD3 protein levels, whereas PHYL NxN did not alter the Siah2-mediated reduction of PHD3 (Figure 1c ). Even at low doses, PHYL 1-130 wild type could inhibit Siah2-dependent PHD3 degradation (Figure 2c and Supplementary Figure 1 ) but higher doses of PHYL 1-130 NxN could not (Supplementary Figure 1) . Nakayama et al. (2004) found that Siah2 was more efficient than Siah1 in destabilizing overexpressed PHD3. We show that Siah1 (human) and Siah1A (mouse) reduced PHD3 protein levels similar to that observed with Siah2 ( Figure 1d ) but Siah1A M180K (a substrate-binding groove mutant) did not alter the PHD3 protein levels (Supplementary Figure 2) , suggesting that the Siah substrate-binding groove is important for PHD ubiquitylation and degradation. Similar observations using the PHYL inhibitory fragment were obtained using another Siah substrate, TIEG-1 (Supplementary Figure 3 ).
PHYL fragment is not targeted for degradation
To investigate whether PHYL fragment functions as an alternate substrate for degradation or simply competes for the Siah-binding site with substrate proteins, we expressed increasing amounts of PHYL with a constant amount of Siah2 or increasing amounts of Siah2 with a constant amount of PHYL. Increasing amounts of Siah2 was not associated with any reduction in PHYL in HEK293 ( Figure 2a ) and other cell lines (data not shown), although a substrate (PHD3) was destabilized under identical conditions ( Figure 2b ). Generally, Siah2 was undetectable due to rapid turnover. Interestingly, increasing amounts of PHYL led to an increase of Siah2 protein levels (Figure 2a) , in HEK293 cells, although this effect was not observed in U2OS cells (data not shown). Siah proteins appear to undergo rapid autoubiquitylation (Depaux et al., 2006) and the finding in HEK293 cells implies that the substrate-binding domain of Siah proteins is involved in this process, or that constant occupancy of the binding groove may inhibit it. By contrast, Siah2 was not stabilized by the expression of high amounts of PHD3 substrate (Figure 2b ), suggesting that flooding cells with Siah2 substrates does not stabilize Siah2. Expression of increasing amounts of PHYL alone resulted in no changes of PHD3 protein levels, whereas Siah2-mediated PHD3 degradation could be inhibited (Figure 2c ). Taken together, these data demonstrate that the VxP motif in PHYL forms a stable, non-degradable association with Siah proteins and blocks their interaction with Siah substrates.
Given that PHD3 degradation in the presence of Siah2 could be inhibited by PHYL binding to Siah2, we investigated the possibility that PHD3 may interact directly with Siah2 through a VxP motif. It was previously reported that residues 143-293 of PHD3 were required for intraction with Siah2, either direct or indirect (Nakayama et al., 2004) . This region of PHD3 contains two VxP motifs at residues 178-180 and 198-200. We mutated each of these separately to NxN, as well as creating a double mutant, but all three proteins were able to be degraded in the presence of Siah2 (Figure 2d ), and this degradation was inhibited by PHYL1-130 (Supplementary Figure 4) , suggesting that either an adaptor protein containing the binding motif is required or that PHD3 can bind to the Siah groove through another mechanism. It was previously published that Siah-dependent PHD3 ubiquitylation in vitro required the presence of reticulocyte lysates (Nakayama et al., 2004) (Figure 3a) . Cell lines did not differ in their proliferation or morphology (data not shown).
Hif-1a was induced in EO771-vector cells after exposure to hypoxia and this was strongly reduced in EO771 cells stably expressing PHYL 1-130 (Figure 3b ). Hif-1a induction in EO771 cells stably expressing PHYL 1-130 NxN did not differ from EO771-vec cells (Figure 3b ), demonstrating the specificity of the ability of PHYL to block Hif-1a upregulation. We measured hypoxia-induced gene expression of known Hif-1 target genes by quantitative reverse transcriptase-PCR. Hypoxia resulted in a 6.4-fold induction of VEGF-A, 3.7-fold for COX4 and 12.5-fold for Rab20 in EO771-vec (Figure 3c ) but this was significantly attenuated in EO771-PHYL 1-130 lines (Figure 3c ). VEGF, COX4 and Rab20 were induced by hypoxia in EO771-PHYL 1-130 NxN to similar levels as in EO771-vec cells (Figure 3c ), demonstrating that the inhibitory function of PHYL can interfere with the role of Siah proteins in regulating the hypoxic response pathway. Similar findings were observed using human 
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Figure 3 PHYL expression inhibits Hif-1a stabilization and Hif-1 induced gene expression. (a) Stable EO771 cells expressing pCDNA3.1, pCDNA3.1-HA-PHYL WT or pCDNA3.1-HA-PHYL NxN. After selection cell lysates were obtained and expression of proteins analysed by western blotting using anti-HA and anti-a-tubulin antibodies. (b) Stable EO771 cell lines were exposed to normoxia or hypoxia for 2 h using anaerogen oxygen depleting sachets. Cell lysates were obtained and expression of proteins analysed by western blotting using anti-Hif-1a, anti-HA and anti-a-tubulin antibodies. (c) Stable EO771 cell lines were exposed to normoxia or hypoxia for 4 h using anaerogen oxygen depleting sachets. mRNA was extracted and reverse transcribed into cDNA. Expression levels of Rab20, Cox4 and VEGF were assessed by quantitative real-time PCR, s.e.m. from three independent experiments.
U2OS cells stably expressing PHYL or PHYL NxN (data not shown).
Hypoxia leads to new blood vessel growth in solid tumors to support the growing tumor. EO771 cells are derived from a spontaneously occurring breast cancer in a C57Bl/6 mouse (Casey et al., 1951) and provide a syngeneic breast cancer model in immunocompetent mice to test the effect of Siah inhibition. We observed that EO771-vec and EO771-PHYL 1-130 NxN tumors grew rapidly compared with EO771-PHYL 1-130 tumors ( Figure 4A ). Tumors expressing PHYL also appeared less vascularized and paler ( Figure 4A ). Analysis of the growth time of the EO771 tumors to reach the maximum ethically allowed diameter of 1 cm showed that mice with EO771-vec expressing tumor cells survived 21.3 ± 0.6 days and mice with EO771-PHYL 1-130 NxN tumors 20.9±0.4 days, showing no significant difference between both groups. However, mice with EO771-PHYL 1-130 tumors survived 27.3 ± 1.1 days, significantly longer than mice with EO771-vec (Po0.05) and EO771-PHYL 1-130 NxN (Po0.05) expressing tumors (n ¼ 7, 6 and 6 for these groups).
Histologically, the tumors showed few areas of necrosis ( Figure 4A) ; however, fewer CD31-positive cells, a marker of endothelial cells, were seen in EO771-PHYL 1-130 tumor sections, compared with EO771-vec or EO771-PHYL 1-130 NxN tumors ( Figure 4B) . Similarly, staining revealed that EO771-PHYL 1-130 tumors expressed lower levels of Hif-1a ( Figure 4C ) suggesting that inhibition of Siah proteins reduces the upregulation of Hif-1a in tumors. Also, the induction of a Hif-1 target, Glut-1, was impaired in EO771-PHYL 1-130 tumors ( Figure 4D ).
Collectively, these findings demonstrate that the PHYL protein fragment can inhibit hypoxic responses in vitro, leading to impaired tumor growth and expression of Hif-1a and its target genes in a breast cancer model.
Discussion
In this study, we have shown that the high affinity Sina interactor, PHYL, can function as an inhibitor of mammalian Siah proteins. Using an expressed protein fragment of PHYL (residues 1-130), we have shown inhibition of Siah function in overexpression studies, suppression of Hif-1a stabilization under hypoxic conditions and in a syngeneic breast cancer model, a slowing of tumor growth and angiogenesis.
Inhibitors of the proteasome, such as bortezomib (Velcade, PS341), have been approved for treatment in cancer therapy (Kane et al., 2003) . To increase target specificity, inhibitors further upstream in the degradation pathway have been sought, with the ubiquitin ligases being a major target. So far, the ubiquitin ligases have not been shown to exhibit a catalytic activity, but merely to function as scaffolds for ubiquitin transfer, suggesting that inhibition will have to target proteinprotein interactions. This study provides proof of principle for targeting the Siah substrate-binding domain to inhibit Siah function, Hif-1a stabilization and tumor growth. By using a protein fragment from the Drosophila PHYL protein to specifically target the substrate-binding groove on Siah, we have shown that competitive inhibition at this site impairs Siah function and suggests that a screen for small molecule inhibitors binding at the same site may be warranted. Similar inhibitor strategies have been used in the past to establish proof of principle for targets such as HDM2 (Bottger et al., 1997; Wasylyk et al., 1999; Chene et al., 2000) , Bcl-2 (Holinger et al., 1999; Wang et al., 2000) and Hif-1a (Freedman et al., 2003) before searches for small molecule inhibitors are carried out. It is generally recognized that the development of small molecules for inhibiting protein-protein interactions may be difficult, though our data, both biochemical and structural, shows that the interaction between Siah and PHYL (and other substrates) is focused on a minimal motif of three amino acids, VxP, with some contribution from distal amino acids. Given the size of this motif (VRP is approximately 350 Da), it is feasible that the binding groove on the Siah protein could accommodate a small molecule (o500 Da) that would preclude binding of the VxP motif and function as a Siah inhibitor.
We have shown here that Siah inhibitors can stabilize substrates PHD1, PHD3 and TIEG-1 in overexpression studies. Siah inhibition was also shown to inhibit Hif-1a stabilization during hypoxia and expression of downstream transcriptional targets such as VEGF, COX4 and Rab20. These findings demonstrate for the first time that the strategy of targeting upstream regulation of Hif-1 through Siah-mediated degradation of PHD proteins is viable. This is important, as it shows that inhibition of Siah protein-protein interaction is mechanistically possible and that it leads to predictable and desired biological effects in vitro and in vivo. It is noteworthy that the outcome was not certain, given that the interaction of Siah with PHD proteins has not been precisely mapped to a well-defined VxP motif in PHD. Although we have shown that the binding groove for the VxP motif is utilized in PHD1 and PHD3 degradation, it does not appear to be utilized for degradation of FIH-1, another component of the hypoxic response pathway. Further investigation of a possible alternative binding site on Siah is required.
Inhibiting the ability of Siah proteins to interact with substrates or adaptors could have effects beyond modulating Hif-1a regulation, given the apparent common usage of the binding groove to recognize VxP motifs within a range of substrate proteins. The effect of therapeutic inhibition of all Siah proteins, in a wide range of tissues, is unknown. In the model presented here, Siah is inhibited in the tumor cells alone. Knockout of individual Siah proteins in mice is not lethal (Dickins et al., 2002; Frew et al., 2003) , although the compound mutant, Siah1a/2 double knockout, dies at or immediately after birth possibly due to impaired hypoxia sensing. Any effects of Siah inhibition in unstressed, adult tissues are still to be determined, although we note that pan-Siah inhibition in EO771 cells did not appear to affect cell growth rate in vitro or cell viability. 
Siah inhibition A Möller et al
The data presented here suggest that the Hif pathway is attenuated by Siah inhibition in vitro (lack of Hif-1a stabilization, reduced Hif transcriptional responses) and in vivo (reduced angiogenesis in tumors) and will therefore contribute partly or wholly to the effects observed in the tumor model. Previously, the nuclear repressor NCoR has been reported as a substrate of Siah2 and that Siah2 is transcriptionally upregulated by estrogen receptor a (ERa) activation (Zhang et al., 1998 ). Siah2 appears to relieve NCoR-mediated repression of ER target genes and therefore enhance ER signaling. We also note that Siah2 gene expression levels are consistently higher in ER-positive human breast cancers, compared with ER-negative tumors (unpublished data). It is therefore possible that Siah inhibition in ER-positive breast tumors may stabilize NCoR and repress estrogen signaling, thus providing an additional mechanism to slow tumor growth in breast cancers. Indeed, we cannot rule out effects on the ER pathway as contributing to the observed tumor growth inhibition in the EO771 model, although the ER status of the EO771 cells remains to be investigated.
In summary, this study provides proof of principle for Siah inhibition at the substrate-binding site as a potential therapeutic strategy to inhibit Hif signaling and slow tumor growth. A search for small molecules binding at the same site has been initiated to investigate their potential as Siah inhibitors and therapeutic value.
Materials and methods

Animal work
C57Bl/6 mice were kept in a sterile animal house with OptiMice caging systems. All procedures were approved by the local animal ethics committee in agreement with state legislations and international guidelines.
Cell culture and transfections
Human embryonic kidney HEK 293 and human osteosarcoma U2OS cells were obtained from ATCC. EO771 cells were a kind gift from Robin Anderson, Peter MacCallum Cancer Centre, Melbourne. All cells were maintained in Dulbecco's modified Eagle's medium containing 10% fetal calf serum and 1% (w/v) penicillin/streptomycin in a humidified incubator at 37 1C and 5% CO 2 . Cells were transiently transfected using the Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) reagent according to the instructions of the manufacturer, or using calcium phosphate transfection. Stable U2OS cell lines were generated by selection in 3 mg/ml Puromycin (Sigma-Aldrich, Saint Louis, MO, USA) for 10 days after transfection and stable EO771 by selection in Geneticin (Invitrogen) for 10 days.
Hypoxia treatment
Cells were treated using anaerogen oxygen depleting sachets (Oxoid, Basingstoke, Hampshire, UK).
Antibodies and plasmids
Antibodies sources were as follows: Flag, b-Actin and a-tubulin (Sigma-Aldrich), Myc (Cell Signalling, Danvers, MA, USA), HA (kind gift of Rick Pearson, Peter MacCallum Cancer Centre, Melbourne) and Hif-1a (BD Biosciences, San Jose, CA, USA). Expression plasmids for TIEG-1, Siah1, Siah1A and Siah2, Phyllopod, PHD1, PHD2 and PHD3 have been described (Johnsen et al., 2002; Nakayama et al., 2004; House et al., 2006) . Mutations were generated using the QuikChange site-directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) according to the instructions of the manufacturer and verified by sequencing.
Immunoblotting Cells were washed with phosphate-buffered saline, detached and collected by centrifugation. Cell pellets were directly lysed in 1 Â SDS sample buffer, boiled and sonified. Proteins contained in cell extracts were separated by SDS-polyacrylamide gel electrophoresis and electrophoretically transferred to PVDF membranes (Immobilon, Millipore, Billerica, MA, USA). After blocking the membrane with 5% skim milk in phosphate-buffered saline with 0.1% Tween20, they were incubated with primary antibodies, extensively washed and further incubated with the appropriate peroxidase-coupled secondary antibodies. Proteins were detected by using the Amersham (Piscataway, NJ, USA) enhanced chemiluminescence system or Pierce (Rockford, IL, USA) Phemtomole for Hif-1a.
Tumor growth EO771 cells (10 5 ) mixed 1:1 with Matrigel (BD Biosciences, San Jose, CA, USA) were injected into the fourth mammary fat pad of 8-12-week-old female C57Bl/6 mice. Tumor dimensions were measured every second day. Mice were either killed 19 days after injection or when the tumor reached the end point defined by the animal ethics committee (1 cm diameter). Tumors were excised, weighed and cut into sections for fixation with 10% normal buffered formalin or fresh frozen for subsequent immunohistochemistry or mRNA and protein extraction.
Immunohistochemistry and antibodies
Paraffin embedded or fresh frozen tumors were serial sectioned and stained with antibodies against CD31 (BD Pharmingen), Glut-1, and Hif-1a (both Novus Biologicals, Littleto, CO, USA) according to instructions of the manufacturer.
